Printer Friendly

Articles from M2 Pharma (December 26, 2018)

1-10 out of 10 article(s)
Title Author Type Words
Alexion Receives Early FDA Approval for Ultomiris in Adults with Paroxysmal Nocturnal Hemoglobinuria. 894
Ayala Pharmaceuticals to Develop and Commercialise AL102 in Combination with BCMA Targeting Agents in Multiple Myeloma. 415
Cerevel Therapeutics Expands Its Board of Directors. 416
European Medicines Agency Grants Orphan Drug Designation for Xeris' Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS). 409
First Patient Treated in Phase 3 Clinical Trial Programme for Ruxolitinib Cream in Atopic Dermatitis. 389
Generex Biotechnology Partner Olaregen Therapeutix Establishes Sales Force and Distribution Team for the Commercial Launch of Excellagen. 471
Janssen Announces European Commission Approval of Darzalex Split Dosing Regimen. 589
Jnana Therapeutics Adds Schreiber, Cali to Board of Directors. 464
Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients. 649
US FDA Extends Action Date for US Merck's Keytruda Supplemental Biologics License Application for KEYNOTE-042 Trial. 1243

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters